Newsroom

MINNEAPOLIS--(BUSINESS WIRE)--Digi International Introduces Digi Ventus™ Managed Connectivity Solutions...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 09.01.2026 FGOV LN IE00BKS2X200 33,638.00 GBP 499,111.11 17.103  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 09.01.2026 IPXE.IM IE00BFD26097 75,002.00 EUR 1,757,286.32 23.430  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 09.01.2026 CPQ IE00BFD2H405 8,800,002.00 USD 477,096,734.56 54.216  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 09.01.2026 FDNU IE00BG0SSC32 2,325,002.00 USD 86,325,528.29 37.129  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 09.01.2026 FTEG.LN IE0009F7UB30 50,002.00 EUR 1,045,680.63 20.913  ...

SAN DIEGO--(BUSINESS WIRE)--Mirador Therapeutics, Inc. (Mirador), a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, today announced key clinical updates and corporate progress. I&I is the second-largest drug spend category in the U.S., yet millions of patients remain untreated or inadequately served by current therapies. Mirador is pioneering precision medicine approaches designed to overcome the efficacy...

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class E RegS XS2768183332 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 4.8% Total Rate: 8.64354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene autoleucel) has received FDA clearance of an IND Amendment (INDa) to use Cellares’ Cell Shuttle™ and Cell Q™ platforms for manufacturing and QC release testing. The clearance allows for the clinical manufacturing and release of rese-cel using Cellares’ fully a...

QUEBEC CITY--(BUSINESS WIRE)--Kobo Resources Inc. (“Kobo” or the "Company") (TSX.V: KRI) is pleased to provide a review of progress achieved during 2025 and key milestones planned for 2026, following a year in which the Company materially advanced its 100%-owned Kossou Gold Project (“Kossou”) toward a maiden Mineral Resource Estimate and expanded its gold exploration portfolio across Côte d’Ivoire, within West Africa, one of the world’s largest gold-producing regions. Edward Gosselin, CEO and D...